Ribavirin effect on experimental Junin virus-induced encephalitis

• Published in: Journal of medical virology Vol. 26; no. 1; p. 79
• Main Authors: Remesar, M C, Blejer, J L, Weissenbacher, M C, Nejamkis, M R
• Format: Journal Article
• Language: English
• Published: United States 01.09.1988
• Subjects: Animals; Arenaviruses, New World - drug effects; Brain - microbiology; Disease Models, Animal; Encephalitis - microbiology; Encephalitis - prevention & control; Hemorrhagic Fever, American - drug therapy; Hemorrhagic Fever, American - physiopathology; Macrophages - microbiology; Peritoneal Cavity - cytology; Rats; Ribavirin - therapeutic use; Ribonucleosides - therapeutic use; Virus Replication - drug effects
• ISSN: 0146-6615
• DOI: 10.1002/jmv.1890260111

Junin virus, the etiological agent of Argentine hemorrhagic fever, produces in man a disease mainly characterized by hemorrhagic alterations, commonly accompanied by neurological symptoms, and leading to 10% mortality. Intracerebral inoculation in 10-day-old rats or intraperitoneal inoculation in 2-day-old rats leads to high mortality due to severe encephalitis. Here, the effect of Ribavirin on these experimental models was tested in order to evaluate the degree of protection achieved against neuropathological manifestations. In intracerebrally infected 10-day-old rats the drug was administered 2 hr before virus inoculation. Doses ranged from 30 to 90 mg/kg body weight. Protection reached 40% for the 60 and 90 mg doses. Intraperitoneally infected 2-day-old rats received the drug in five 30-mg daily doses, starting the same day as virus inoculation. Survival was 73%. Viral replication within peritoneal macrophages dropped markedly, leading to much lower CNS viral titres. Together with results reported in primates, our findings support further studies on Ribavirin, with a view to eventual trials in humans.